Current global situation of Chagas disease.
DOI:
https://doi.org/10.32776/revbiomed.v32i2.904Abstract
Trypanosoma cruzi has existed in humans for <9000 years 1. Parasite, vector and human disease were described by Carlos Chagas in 1909 2. Vectorial and congenital transmissions account for ~70% and 26% of new infections, respectively. The clinical course of Chagas Disease (CD) is generally presented with acute parasitemic phase, clinically asymptomatic indeterminate phase, and chronic phase when patients develop cardiac, colon, or neurological disorders. Heart failure is recognized as the major cause of death in CD patients. The global productivity gain by treating acute or chronic CD and preventing heart failure and death is estimated to be $8 billion US dollars in 2021-2030 3. Thus, just the economic benefits make a strong case for new investments in controlling this disease.Downloads
Additional Files
Published
Issue
Section
License
Those authors who have publications with this magazine accept the following terms:
Authors will keep their copyright and guarantee the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons Recognition License that allows third parties to share the work whenever its author is indicated and his first publication in this magazine. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (eg, deposit it in an institutional telematic file or publish it in a monographic volume) whenever the initial publication in this journal is indicated. Authors are allowed and advised to disseminate their work through the Internet (eg in institutional telematic archives or on their website) after the submission has been accepted and published, which can produce interesting exchanges and increase citations of the published work.
(See The effect of open access)
